Mara G. Aspinall
Known title: DirectorCIK: 0001623049
Mara G. Aspinall's purchase track record
Mara G. Aspinall has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/25/2022 | OSUR | $25K | +18.6% | +49.6% | -4.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| OSUR | ▲ Buy | Grant | 71,017 | $0 | 5/14/2025 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 6,666 | $18K | 5/13/2025 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 8,636 | — | 5/23/2024 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 6,619 | $35K | 5/14/2024 | View on chart |
| OSUR | ▲ Buy | Grant | 24,691 | $0 | 5/14/2024 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 3,825 | — | 6/2/2023 | View on chart |
| OSUR | ▲ Buy | Grant | 24,517 | $0 | 5/16/2023 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 5,400 | $30K | 5/15/2023 | View on chart |
| OSUR | ▲ Buy | Open Market | 6,000 | $25K | 8/25/2022 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 830 | $0 | 6/10/2022 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 6,745 | $27K | 6/3/2022 | View on chart |
| OSUR | ▲ Buy | Grant | 24,983 | $100K | 6/3/2022 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 2,957 | $16K | 5/16/2022 | View on chart |
| OSUR | ▲ Buy | Grant | 20,000 | $105K | 5/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Castle Biosciences Publishes AD Molecular Testing Study, Opens New Lab
Castle Biosciences highlighted a new study that shows a strong need for molecular testing in atopic dermatitis, supporting its AdvanceAD‑Tx product. The company also announced a new laboratory and office facility in Scottsdale, Arizona, expanding its testing capabilities. These developments reinforce the company's focus on precision diagnostics for skin conditions.
Castle Biosciences Publishes AD Molecular Testing Study, Opens New Lab. Castle Biosciences highlighted a new study that shows a strong need for molecular testing in atopic dermatitis, supporting its AdvanceAD‑Tx product. The company also announced a new laboratory and office facility in Scottsdale, Arizona, expanding its testing capabilities. These developments reinforce the company's focus on precision diagnostics for skin conditions.